FDA efforts to oversee foreign drug manufacturing remain inadequate to ensure safety; Supreme Court wrestles with OxyContin maker’s bankruptcy deal

Taking stock of the drug industry, from the lab to the medicine chest

December 4, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | FDA efforts to oversee foreign drug manufacturing remain inadequate to ensure safety, analysis finds FDA budgets and staffing held steady, though resources allocated for each inspection surged and more plants were cited for serious violations. By Ed Silverman Supreme Court wrestles with OxyContin maker's bankruptcy deal The justices seemed by turns relucant to break up an exhaustively negotiated agreement, but also leery of somehow rewarding the Sacklers. By Associated Press STAT+ | Roche to acquire obesity-focused Carmot Therapeutics for $2.7 billion Roche said Carmot's line of weight loss candidates could complement its own pipeline, in another sign of the booming obesity market. By Andrew Joseph JIM LO SCALZO/POOL/AFP via Getty Images STAT+ | Official: FDA needs staff influx to meet gene therapy needs The FDA's Peter Marks says he'll need more staff to get a new gene therapy initiative for rare diseases up and running. By Sarah Owermohle STAT+ | How sickle cell became the first disease treated by CRISPR CRISPR has the potential to treat hundreds of diseases. STAT examines how sickle cell was the ideal test case for the gene-editing tool. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser